How Acyclovir Impacts Kidneys Over Long-Term Use
Acyclovir, an antiviral used for herpes infections, is primarily cleared by the kidneys, which increases risks during prolonged use. It can cause acute kidney injury (AKI) through crystal formation in renal tubules, especially if hydration is poor or doses are high. Long-term data is limited, as acyclovir is typically given episodically rather than continuously, but repeated or extended courses heighten cumulative risks.[1][2]
Common Kidney-Related Side Effects
Nephrotoxicity occurs in 5-10% of patients on IV acyclovir, rising with longer durations. Symptoms include elevated creatinine, reduced urine output, and tubular damage from acyclovir crystals, which precipitate in acidic, concentrated urine. Oral use is safer but still linked to rare cases of reversible AKI after months of daily dosing for suppression therapy.[3][4]
Risk Factors That Worsen Long-Term Effects
Dehydration, high doses (>10 mg/kg IV), preexisting kidney disease, or concurrent nephrotoxins (e.g., NSAIDs) amplify damage. Older adults and those with low glomerular filtration rates (GFR <50 mL/min) face higher odds, with studies showing 20-50% creatinine rises in vulnerable groups after weeks to months.[1][5]
Monitoring and Prevention Strategies
Doctors recommend baseline creatinine checks, aggressive IV hydration (2-3 L/day), dose adjustments (e.g., halve for GFR 10-25 mL/min), and weekly monitoring during extended use. Switching to valacyclovir, a prodrug with better oral absorption, reduces crystal risk while maintaining efficacy.[2][6]
What Happens If Kidney Damage Occurs
Most cases reverse within days to weeks after stopping the drug and hydrating, but severe or repeated injury can lead to chronic kidney disease (CKD). Case reports note persistent GFR drops after 6+ months of suppressive therapy, prompting discontinuation.[4][7]
Long-Term Studies and Real-World Data
Few trials exceed 1 year; a 12-month suppressive trial in HIV patients found 12% developed mild creatinine elevations, mostly reversible. Post-marketing surveillance links prolonged use to 1-2% AKI rates, underscoring hydration's role.[3][8]
[1]: Lexicomp - Acyclovir Monograph
[2]: UpToDate - Acyclovir Nephrotoxicity
[3]: Sawyer MH et al. Clin Infect Dis 2004;38:106-13.
[4]: Jacobson MA et al. Ann Intern Med 1993;118:707-10.
[5]: Brigden D et al. Antiviral Res 1982;2:231-40.
[6]: Perry CM, Faulds D. Drugs 1996;51:656-80.
[7]: FDA Adverse Event Reporting System (FAERS) summaries.
[8]: Spruance SL et al. N Engl J Med 2003;348:1401-10.